TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE
نویسندگان
چکیده
منابع مشابه
Cladribine in aggressive forms of multiple sclerosis.
Cladribine (2-chlorodeoxyadenosine) is an immunosuppressant drug previously evaluated in multiple sclerosis (MS) with variable results. We report six patients with aggressive relapsing MS who despite a poor response to other therapies had a favourable clinical evolution after cladribine. Four women and two men with a rapid increase in the number and severity of relapses leading to increasing di...
متن کاملCladribine in the treatment of multiple sclerosis
ISSN 2041-6792 10.4155/CLI.10.32 © 2011 Future Science Ltd Treatment with cladribine leads to a preferential and sustained reduction in lymphocytes and monocytes, resulting in long-lasting depletion of CD4+ and CD8+ T cells. In the Phase III placebo-controlled trial in relapsing–remitting multiple sclerosis (the CLARITY study), oral cladribine at 96 weeks significantly reduced annual relapse ra...
متن کاملPopulation Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
PURPOSE The aims of this study were to characterize the concentration-time course of cladribine (CdA) and its main metabolite 2-chloroadenine (CAde), estimate interindividual variability in pharmacokinetics (PK), and identify covariates explaining variability in the PK of CdA. METHODS This population PK analysis was based on the combined dataset from four clinical studies in patients with mul...
متن کاملTreating depressed multiple sclerosis patients
10.2217/14750708.4.3.339 © 2 Approximately one in two multiple sclerosis patients will develop a major depression over the course of their lifetime. This is associated with a decreased quality of life and a high risk of completed suicide. A literature review suggests pharmacotherapy with a selective serotonin-reuptake inhibitor or tricyclic antidepressant is effective, the former likely better ...
متن کاملCladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
INTRODUCTION Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence. It was anticipated that new approaches to treatment, including oral agents such as cladribine ta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurology, Neurosurgery & Psychiatry
سال: 2016
ISSN: 0022-3050,1468-330X
DOI: 10.1136/jnnp-2016-315106.121